Five Prime: Phase 2 Cabiralizumab/Opdivo Study Misses Endpoint
February 18 2020 - 10:35AM
Dow Jones News
By Colin Kellaher
Five Prime Therapeutics Inc. on Tuesday said it was informed by
Bristol-Myers Squibb Co. that a Phase 2 study testing the
combination of Five Prime's cabiralizumab with Bristol's Opdivo in
patients with advanced pancreatic cancer didn't meet its primary
endpoint.
Five Prime, a South San Francisco, Calif., clinical-stage
biotechnology company, said Bristol has no near-term plans for
additional sponsored development of cabiralizumab.
However, Five Prime said the New York drug maker will continue
to support the evaluation of cabiralizumab in select, ongoing
investigator-sponsored trials and may continue to assess future
development opportunities for the investigational antibody.
Five Prime noted that Bristol, which acquired rights to
cabiralizumab in October 2015 under an exclusive worldwide license
and collaboration agreement, also reported that no new safety
signals were observed in the study.
Shares of Five Prime slipped 4.2% to $4.34 in early trading
Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 18, 2020 10:20 ET (15:20 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Mar 2023 to Mar 2024